Drugs / PTH-IA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07541209 | May 2026 → Jun 2029 expected | metaphyseal chondrodysplasia, Jansen type | National Institute of Dental and Craniofacial Research (NIDCR) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTH-IA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07541209 ↗ |
| Modality | Peptide | “PTH-IA is a 30-amino acid peptide” NCT07541209 ↗ |
| Route | Subcutaneous | “PTH-IA administered subcutaneously twice a day” NCT07541209 ↗ |